GNPX - ジェンプレックス （Genprex Inc.）

Corporate Presentation to Highlight Company''s Gene Therapies for Cancer and Diabetes AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

Las Vegas, USA, April 14, 2022 (GLOBE NEWSWIRE) -- Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Small-cell Lung Cancer Pipeline constitutes 100+ key companies continuously working towards developing 100+ Small-cell Lung Cancer treatment therapies, analyzes DelveInsight DelveInsight''s Small-cell Lung Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Small-cell Lung Cancer pipeline domain. Some of the essential takeaways from the Small-cell Lung Cancer Pipeline report: DelveInsight''s Small-cell Lung Cancer Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ Small-cell Lung Cancer treatment pipeline therapies. Some of the key Small-cell Lung Cancer companies proactively working to develop potential drug candidates to improve the Small-cell Lung Cancer treatment scenario include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee''s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen, Cybrexa Therapeutics, and many others.

Real Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks.

Genprex <> said its collaborators published positive preclinical data for the use of its ONCOPREX Nanoparticle Delivery System to deliver a FAS DNA plasmid to treat

Genprex Inc (GNPX) shares closed this week 69.5% higher than it did at the end of last week. The stock is currently up 69.5% year-to-date, down 42.8% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $3.62 and as low as $1.51 this week.Shares closed 71.2% below its 52-week high and 89.7% above its 52-week low.Trading volume this week was 67.5% lower than the 10-day average and 8.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 14.5% lower than its 5-day moving average, 34.1% higher than its 20-day moving average, and 2.7% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -26755.6% The company's stock price performance over the past 12 months lags the peer average by 389.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Real Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks.

Genprex <> said its collaborators published positive preclinical data for the use of its ONCOPREX Nanoparticle Delivery System to deliver a FAS DNA plasmid to treat

Genprex Inc (GNPX) shares closed this week 69.5% higher than it did at the end of last week. The stock is currently up 69.5% year-to-date, down 42.8% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $3.62 and as low as $1.51 this week.Shares closed 71.2% below its 52-week high and 89.7% above its 52-week low.Trading volume this week was 67.5% lower than the 10-day average and 8.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 14.5% lower than its 5-day moving average, 34.1% higher than its 20-day moving average, and 2.7% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -26755.6% The company's stock price performance over the past 12 months lags the peer average by 389.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

New York , June 23, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Companys clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Companys

Earnings results for Genprex , Analyst Opinion on Genprex , Earnings and Valuation of (NASDAQ:GNPX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX) appeared first on .